Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics

Reuters10-09

Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics

Acurx Pharmaceuticals Inc. announced that it has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, including composition-of-matter claims. This patent expands the company's growing international intellectual property portfolio for its ACX-375C program, which targets difficult-to-treat bacterial infections. In addition to the new Australian patent, similar patents have already been granted in the United States, Israel, Japan, and India, with further applications underway in other countries. The company stated that its lead DNA Polymerase IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile infection, while new preclinical compounds are being developed for a range of serious bacterial infections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY94088) on October 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574159074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574159074","market":"us","top_or_hot":-1,"title":"Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acurx Pharmaceuticals Inc. announced that it has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, including composition-of-matter claims. This patent expands the company's growing international intellectual property portfolio for its ACX-375C program, which targets difficult-to-treat bacterial infections. In addition to the new Australian patent, similar patents have already been granted in the United States, Israel, Japan, and India, with further applications underway in other countries. The company stated that its lead DNA Polymerase IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile infection, while new preclinical compounds are being developed for a range of serious bacterial infections.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY94088) on October 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-09 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acurx Pharmaceuticals Inc. announced that it has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, including composition-of-matter claims. This patent expands the company's growing international intellectual property portfolio for its ACX-375C program, which targets difficult-to-treat bacterial infections. In addition to the new Australian patent, similar patents have already been granted in the United States, Israel, Japan, and India, with further applications underway in other countries. The company stated that its lead DNA Polymerase IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile infection, while new preclinical compounds are being developed for a range of serious bacterial infections.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY94088) on October 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACXP","symbol_name":"Acurx Pharmaceuticals, LLC*","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL3lSMlD:1","article_id":"2574159074","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574159074","pubTimestamp":1760009468,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics. Acurx Pharmaceuticals Inc. announced that it has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, including composition-of-matter claims. This patent expands the company's growing international intellectual property portfolio for its ACX-375C program, which targets difficult-to-treat bacterial infections. In addition to the new Australian patent, similar patents have already been granted in the United States, Israel, Japan, and India, with further applications underway in other countries. The company stated that its lead DNA Polymerase IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile infection, while new preclinical compounds are being developed for a range of serious bacterial infections.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellig","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACXP":"Acurx Pharmaceuticals, LLC*","BK4139":"生物科技","BK4563":"昨日强势股","BK4539":"次新股"},"translate_title":"Acurx Pharmaceuticals获得DNA聚合酶IIIC抑制剂澳大利亚专利，扩大了对新型抗生素的全球保护","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACXP":0.9},"content_text":"Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics\n    \n\n        Acurx Pharmaceuticals Inc. announced that it has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, including composition-of-matter claims. This patent expands the company's growing international intellectual property portfolio for its ACX-375C program, which targets difficult-to-treat bacterial infections. In addition to the new Australian patent, similar patents have already been granted in the United States, Israel, Japan, and India, with further applications underway in other countries. The company stated that its lead DNA Polymerase IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile infection, while new preclinical compounds are being developed for a range of serious bacterial infections.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY94088) on October 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574159074","isCrawlerRequest":true}